PPARG-related familial partial lipodystrophy: genes and variants
Explore variant evidence for PPARG-related familial partial lipodystrophy across 1 analyzed protein (PPARG). Linked ClinVar records include 7 pathogenic or likely pathogenic variants, 3 variants of uncertain significance and 1 with conflicting classifications.
Coverage includes proteins already analyzed in CATVariant, not every gene involved in this condition. Database links are associations, not an assessment of clinical gene–disease validity. Computable evidence prioritizes variants for expert review and does not reclassify them. Counts refer to the selected disease label.
Data updated 2026-10-15. Automated aggregation, not a clinical review date.
Download variant evidence (CSV)
Genes linked to PPARG-related familial partial lipodystrophy
PPARG: Peroxisome proliferator-activated receptor gamma
It drives adipocyte differentiation, lipid storage, and insulin-sensitive metabolic programs in response to endogenous lipids and thiazolidinedione drugs. Dominant-negative variants cause familial partial lipodystrophy type 3 with severe insulin resistance and dyslipidemia.
7 ClinVar pathogenic / likely pathogenic and 4 uncertain variants in PPARG have source records linked to PPARG-related familial partial lipodystrophy. Association strength is not clinical gene validity.
ClinVar pathogenic and likely pathogenic variants linked to PPARG-related familial partial lipodystrophy
| Variant | Position | Protein part | Clinical label |
|---|---|---|---|
| PPARG R164Q | 164 | Nuclear receptor | Pathogenic / likely pathogenic (★★) |
| PPARG R425H | 425 | NR LBD | Pathogenic / likely pathogenic (★★) |
| PPARG P495L | 495 | NR LBD | Pathogenic / likely pathogenic (★★) |
| PPARG R164W | 164 | Nuclear receptor | Pathogenic / likely pathogenic |
| PPARG P214L | 214 | Interaction with FAM120B | Pathogenic / likely pathogenic |
| PPARG V318M | 318 | NR LBD | Pathogenic / likely pathogenic |
| PPARG F388L | 388 | NR LBD | Pathogenic / likely pathogenic |
Diseases related to PPARG-related familial partial lipodystrophy
- Type 2 diabetes mellitus, also linked to PPARG
- Diabetes mellitus, also linked to PPARG
- Colon carcinoma, also linked to PPARG
Frequently asked questions
Which genes have records linked to PPARG-related familial partial lipodystrophy?
This view contains 1 analyzed proteins: PPARG. Links come from clinical records and association databases. They do not imply that every listed gene is a validated cause, and missing genes may not yet be analyzed.
What do the clinical classifications mean?
Linked records include 7 pathogenic or likely pathogenic variants, 3 variants of uncertain significance and 1 with conflicting classifications. Labels summarize source records; multi-condition records may not make a separate assertion for this disease. Check the original record and review status.
Does the evidence score change a VUS classification?
No. 0 VUS or conflicting variants reach the likely-pathogenic points range on the computable criteria available here. This is a research prioritization signal, not a clinical classification. Patient, family and other required evidence may be missing.
Can I download the variant evidence?
Download the CSV for all 15 variants in the selected disease scope, including clinical labels, review status, evidence criteria, predictor scores, functional measurements and population frequency where available.
About this data
Variant–disease links come from ClinVar, Open Targets and UniProt, pooled from eligible public CATVariant analyses of each human protein. Evidence scores use the ACMG/AMP Bayesian points scale with computable criteria only (position among known disease variants, rarity in gnomAD, calibrated predictors, deep mutational scanning); there is no family or patient data, so they prioritise variants for expert review and never classify them.
Download every variant as CSV · Browse all diseases · Methods · About the Center